Skip to main content
. 2023 Apr 4;52(4):1243–1256. doi: 10.1093/ije/dyad037

Table 1.

Baseline characteristics of participants in the trial (SPRINT or ACCORD-BP) according to the treatment assignment

Variables Intensive treatment group (target SBP <120 mmHg; N = 5334) Standard treatment group (target SBP <140 mmHg; N = 5338)
Age, mean (SD), year 65.4 (8.3) 65.6 (8.5)
Female, % 2191 (41.1) 2161 (40.5)
Race/ethnicity, %
 Non-Hispanic White 3165 (58.3) 3102 (58.1)
 Non-Hispanic Black 1378 (25.8) 1469 (27.5)
 Hispanic 489 (9.2) 479 (9.0)
 Other 302 (5.7) 288 (5.4)
Education status, %
 Less than college 3592 (67.3) 3538 (66.3)
 College or above 1742 (32.7) 1800 (33.7)
Uninsured, % 673 (12.6) 666 (12.5)
Living alone, % 1317 (24.7) 1382 (25.9)
Smoking, % 676 (12.7) 719 (13.5)
SBP, mean (SD), mmHg 139.2 (15.8) 139.5 (15.5)
BMI, mean (SD), kg/m2 31.1 (5.4) 31.0 (5.2)
Total cholesterol, mean (SD), mg/dL 191.8 (43.0) 190.9 (42.1)
HDL cholesterol, mean (SD), mg/dL 49.7 (14.2) 49.9 (14.6)
eGFR, mL/min/1.73 m2, %
 ≥90 1548 (29.0) 1539 (28.9)
 60 to <90 2665 (50.0) 2666 (49.9)
  45 to <60 768 (14.4) 796 (14.9)
 <45 353 (6.6) 337 (6.3)
Clinical CVD, % 1233 (23.1) 1193 (22.4)
Statin use, % 2781 (52.1) 2872 (53.8)
Antihypertensive use medications, %
 0 534 (10.1) 559 (10.9)
 1 1786 (33.5) 1800 (33.7)
 ≥2 3014 (56.5) 2959 (55.4)
History of diabetesa 2239 (42.0) 2244 (42.0)
10-year Framingham CVD risk %, median (IQR) 22.7 (19.6) 22.6 (19.4)
10-year ASCVD risk %, median (IQR) 22.3 (12.8) 22.5 (13.0)

SPRINT, Systolic Blood Pressure Intervention Trial; ACCORD-BP, Action to Control Cardiovascular Risk in Diabetes Blood Pressure; BMI, body mass index; SBP, systolic blood pressure; HDL, high-density lipoprotein; eGFR, estimated glomerular filtration rate; CVD, cardiovascular disease; SD, standard deviation; IQR, interquartile range; ASCVD, atherosclerotic cardiovascular disease.

a

History of diabetes was labelled as 0 for the SPRINT participants and 1 for the ACCORD-BP participants.